SCHEMBL19998591

SCHEMBL19998591

C[C@H]1CC(=O)N(c2ccccc2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.57
ALDH1A1 P00352 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 2/20 0.57
USP2 O75604 1/20 0.57
HPGD P15428 1/20 0.57
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
DPP4 P27487 1/20 0.48
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
MEN1 O00255 2/20 0.45
NPC1 O15118 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TSHR P16473 2/20 0.45
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435086 1.00 POLB (0.57) POLBALDH1A1SMN1; SMN2MAPTUSP2
Methyl Alcohol SCHEMBL28445158 0.96 POLB (0.54) POLBALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL12235705 0.81 RXFP1 (0.52) POLBALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL16474469 0.81 ALDH1A1 (0.54) POLBALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL27048510 0.81 MEN1 (0.51) POLBALDH1A1MAPTDPP4MEN1
SCHEMBL16474467 0.81 ALDH1A1 (0.54) POLBALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL7909433 0.81 ALDH1A1 (0.54) POLBALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL22554286 0.81 RXFP1 (0.52) POLBALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL22554265 0.81 RXFP1 (0.52) POLBALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL20901728 0.79 POLB (0.56) POLBALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-06-11 US disclosed
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-10-24 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 951/4885ALDH1A1 1172/4885SMN1; SMN2 3214/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885
US-20200181086-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 796/4885ALDH1A1 1220/4885SMN1; SMN2 3239/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 951/4885ALDH1A1 1172/4885SMN1; SMN2 3214/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885
US-20190322624-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.